All In Biotech

Drug Trial Radar · NCT06372145

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

2,500

Planned (sponsor's estimate)

Start

Apr 16, 2024

Primary completion

Apr 30, 2029

Study completion Apr 30, 2029

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Apr 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b LTS (LTS16004) or 1 of the 4 Phase 3 tolebrutinib pivotal trials (GEMINI 1 \[EFC16033\], GEMINI 2 \[EFC16034\], HERCULES \[EFC16645\], or PERSEUS \[EFC16035\]). SUBSTUDY: ToleDYNAMIC substudy

Conditions

  • Relapsing Multiple Sclerosis
  • Secondary Progressive Multiple Sclerosis
  • Progressive Relapsing Multiple Sclerosis

Interventions

  • TolebrutinibDrug

    Pharmaceutical form:Tablet-Route of administration:oral

  • PlaceboDrug

    Pharmaceutical form:Tablet-Route of administration:oral

  • TeriflunomideDrug

    Pharmaceutical form:Tablet-Route of administration:oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) and AEs leading to permanent study intervention discontinuationTime frame: From baseline until the End of study approximately 4 years per participant
  2. Number of Participants with Potentially clinically significant abnormalities (PCSAs)Time frame: From baseline until the End of study approximately 4 years per participant

Locations

352 sites in 47 countries. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham- Site Number : 8400013

    Birmingham, Alabama

  • ~North Central Neurology Associates, PC- Site Number : 8400009

    Cullman, Alabama

  • Center for Neurology and Spine- Site Number : 8400089

    Phoenix, Arizona

  • Collaborative Neuroscience Research- Site Number : 8400045

    Los Alamitos, California

  • USC- Site Number : 8400143

    Los Angeles, California

  • University of California San Diego Medical Center- Site Number : 8400101

    San Diego, California

  • Regina Berkovich, MD, PhD- Site Number : 8400059

    West Hollywood, California

  • University of Colorado- Site Number : 8400012

    Denver, Colorado

  • Advanced Neurosciences Research- Site Number : 8400025

    Fort Collins, Colorado

  • Georgetown University Medical Center- Site Number : 8400119

    Washington D.C., District of Columbia

  • SFM Clinical Research, LLC- Site Number : 8400029

    Boca Raton, Florida

  • University of Florida Health- Site Number : 8400159

    Gainesville, Florida

  • Neurology Associates- Site Number : 8409902

    Maitland, Florida

  • University of Miami- Site Number : 8400063

    Miami, Florida

  • Aqualane Clinical Research- Site Number : 8400027

    Naples, Florida

  • Axiom Clinical Research of Florida- Site Number : 8400001

    Tampa, Florida

  • University of South Florida- Site Number : 8409905

    Tampa, Florida

  • Velocity Clinical Research- Site Number : 8409903

    Savannah, Georgia

  • Consultants In Neurology- Site Number : 8409906

    Northbrook, Illinois

  • Springfield Clinic, LLP- Site Number : 8400071

    Springfield, Illinois

  • Indiana University Health, Inc- Site Number : 8400039

    Fort Wayne, Indiana

  • University of Kansas Medical Center- Site Number : 8400023

    Kansas City, Kansas

  • University of Kentucky- Site Number : 8400106

    Lexington, Kentucky

  • Norton Neurology MS Services- Site Number : 8400127

    Louisville, Kentucky

  • The NeuroMedical Center- Site Number : 8400057

    Baton Rouge, Louisiana

  • Ochsner Clinic Foundation- Site Number : 8400107

    New Orleans, Louisiana

  • Tufts Medical Center- Site Number : 8400072

    Boston, Massachusetts

  • University of Massachusetts- Site Number : 8400014

    Worcester, Massachusetts

  • Wayne State University- Site Number : 8400046

    Detroit, Michigan

  • Michigan Institute Neuro Disorders- Site Number : 8400058

    Farmington Hills, Michigan

  • Memorial Healthcare Institute for Neuroscience- Site Number : 8400033

    Owosso, Michigan

  • Minneapolis Clinic of Neurology- Site Number : 8400051

    Golden Valley, Minnesota

  • Mayo Clinic- Site Number : 8400111

    Rochester, Minnesota

  • Sharlin Health & Neurology- Site Number : 8400093

    Ozark, Missouri

  • Missouri Baptist Medical Center- Site Number : 8400019

    St Louis, Missouri

  • Lou Ruvo Center for Brain Health- Site Number : 8400117

    Las Vegas, Nevada

  • University of New Mexico- Site Number : 8400032

    Albuquerque, New Mexico

  • Mount Sinai Medical Center- Site Number : 8400038

    New York, New York

  • NYU Langone South Shore Neurologic Associates- Site Number : 8400100

    Patchogue, New York

  • Neurology Associates of Stony Brook- Site Number : 8400042

    Stony Brook, New York

Showing 40 of 352 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.